Key result
Pulmonary hypertension in CKD is linked to higher mortality and MACE.
Why the study?
The study was conducted to estimate the predictors, prevalence, and prognostic role of pulmonary hypertension in patients with chronic kidney disease.
Meta-Analysis
Pulmonary hypertension is a significant prognostic marker for adverse cardiovascular outcomes and mortality in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
PH may flag high-risk CKD patients for closer surveillance; confirms prognostic link but leaves open whether PH-targeted therapy improves outcomes.
BACKGROUND: To estimate the predictors, prevalence and prognostic role of pulmonary hypertension (PH) in patients with chronic kidney disease (CKD) using meta-analysis. METHODS: The PubMed, EmBase, and the Cochrane library were systematically searched for eligible studies from inception till May 2024. All of pooled analyses were performed using the random-effects model. Moreover, PH in CKD patients is also associated with poor prognosis, including all-cause mortality, major cardiovascular events, and cardiac death. CONCLUSION: This study systematically identified risk factors for PH in CKD patients, and PH were associated with poor prognosis. Therefore, patients with high prevalence of PH should be identified for treatment.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2024) conducted a meta-analysis in Chronic kidney disease. Pulmonary hypertension was evaluated on Poor prognosis (all-cause mortality, major cardiovascular events, and cardiac death) (p=<0.001). Pulmonary hypertension in patients with chronic kidney disease is associated with poor prognosis, including all-cause mortality, major cardiovascular events, and cardiac death (P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: